|
|||||
|
|
| 中美创新药物风险投资机制比较分析 | |
| 引用本文： | 丁锦希,马依林. 中美创新药物风险投资机制比较分析[J]. 中国新药杂志, 2011, 0(23) |
| 作者姓名： | 丁锦希 马依林 |
| 作者单位： | 中国药科大学国际医药商学院; |
| 基金项目： | 国家社会科学基金(10CFX055); 国家知识产权局软科学研究项目(SS11-A-21) |
| 摘 要： | 目的:比较分析中美创新药物研发风险投资机制,为完善我国的创新药物风险投资机制提供理论参考。方法:以风险投资额、资本结构、投入阶段和退出机制为指标对中美创新药物研发的风险投资现状进行量化对比,并系统分析相关政策工具。结果:我国创新药物风险投资机制存在规模小、来源单一、投入阶段前倾以及退出效率低等问题,需进一步政策调控和引导。结论:我国应在统一监管机构、健全激励政策以及优化税收政策等方面完善创新药物风险投资机制。 |
| 关 键 词： | 创新药物 风险投资 政策比较 |
Comparison and analysis of the venture capital mechanisms of innovative drugs in China and America |
|
| DING Jin-xi,MA Yi-lin. Comparison and analysis of the venture capital mechanisms of innovative drugs in China and America[J]. Chinese Journal of New Drugs, 2011, 0(23) | |
| Authors: | DING Jin-xi MA Yi-lin |
| Affiliation: | DING Jin-xi,MA Yi-lin(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China) |
| Abstract: | Objective: To compare and analyze the venture capital mechanisms of innovative drugs in China and America,and to provide theoretical references for the improvement of Chinese venture capital mechanism of innovative drugs.Methods: We compared the venture capital mechanisms of innovative drugs in China and America via quantization analysis and comparison of related policy frame.The VC investment,capital structure,investment stage and capital exit mechanism were used as indexes.Results: In China,there are some... |
| Keywords: | innovative drugs venture capital policy comparison |
| 本文献已被 CNKI 等数据库收录！ | |